Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20701420 | 1.00 | FKBP1A (0.46) | FKBP1ASIGMAR1CTSLSYKNPFFR1 | |
| SCHEMBL20701308 | 0.93 | SIGMAR1 (0.45) | FKBP1ASIGMAR1CTSLSYKNPFFR1 | |
| SCHEMBL20701304 | 0.93 | SIGMAR1 (0.45) | FKBP1ASIGMAR1CTSLSYKNPFFR1 | |
| SCHEMBL15122636 | 0.84 | HPGD (0.45) | FKBP1ACTSLHTR2C | |
| SCHEMBL15122638 | 0.84 | HPGD (0.45) | FKBP1ACTSLHTR2C | |
| SCHEMBL31148977 | 0.80 | HTT (0.43) | FKBP1ACTSLHTTHTR2C | |
| SCHEMBL30428928 | 0.80 | HPGD (0.43) | FKBP1ACTSLHTTHTR2C | |
| SCHEMBL14814073 | 0.77 | NPC1 (0.44) | FKBP1ACTSLHTR2C | |
| SCHEMBL1997238 | 0.77 | FKBP1A (0.64) | FKBP1ASIGMAR1CTSLPREP | |
| SCHEMBL6787227 | 0.77 | FKBP1A (0.64) | FKBP1ASIGMAR1CTSLPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186270-B1 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC (CA) | 2020-02-19 | — | — | EP | disclosed |
| US-10537652-B2 | Cyclic urea compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2020-01-21 | — | — | US | disclosed |
| US-20190151484-A2 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2019-05-23 | — | — | US | disclosed |
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | VIDA THERAPEUTICS, INC. (CA) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | GZMB, CTSB, SERPINB1 | FKBP1A 1088/4885SIGMAR1 4267/4885CTSL 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.